MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Up 104.7% in February

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 30,700 shares, an increase of 104.7% from the January 31st total of 15,000 shares. Currently, 3.1% of the shares of the company are short sold. Based on an average daily volume of 31,600 shares, the days-to-cover ratio is currently 1.0 days.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Robert W. Baird reduced their price target on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. HC Wainwright raised their price objective on MiNK Therapeutics from $9.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th.

MiNK Therapeutics Trading Down 1.6 %

Shares of NASDAQ:INKT traded down $0.15 on Friday, reaching $8.95. The company had a trading volume of 11,343 shares, compared to its average volume of 48,254. The firm has a market capitalization of $35.47 million, a PE ratio of -2.29 and a beta of 0.17. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00. The firm’s 50 day simple moving average is $8.63 and its 200-day simple moving average is $7.75.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.